Barclays analyst Gena Wang raised her price target for BioCryst Pharmaceuticals to $8 from $6 following a deep dive ahead of the BCX7353 APeX-2 Phase 3 readout in Q2 for the prevention of hereditary angioedema attacks. The analyst believes APeX-2 is “well powered to allow for statistical significance” with only greater than 25-30% attack reduction. However, she continues to see some risk in the trial outcome and a high bar for future commercial uptake. Wang keeps an Equal Weight rating on BioCryst.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.